Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
Mutant cancer subpopulations have the potential to derail durable patient responses to molecularly targeted cancer therapeutics, yet the prevalence and size of such subpopulations are largely unexplored. We employed the sensitive and quantitative Allele-specific Competitive Blocker PCR approach to c...
Main Authors: | Meagan B. Myers, Malathi Banda, Karen L. McKim, Yiying Wang, Michael J. Powell, Barbara L. Parsons |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-04-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558616000282 |
Similar Items
-
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
by: Lucie C Kompier, et al.
Published: (2010-11-01) -
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
by: Chen Mao, et al.
Published: (2012-01-01) -
Oncogenic mutations of PIK3CA and HRAS in carcinoma of cervix in South Indian women
by: Geetha kumari Konathala, et al.
Published: (2017-12-01) -
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
by: Irene Lurkin, et al.
Published: (2010-01-01) -
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
by: Giovanni Brandi, et al.
Published: (2012-01-01)